Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $91.9 million.

  • Seres Therapeutics' Non-Current Assets fell 1310.6% to $91.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $386.3 million, marking a year-over-year decrease of 3940.86%. This contributed to the annual value of $101.1 million for FY2024, which is 4479.17% down from last year.
  • Latest data reveals that Seres Therapeutics reported Non-Current Assets of $91.9 million as of Q3 2025, which was down 1310.6% from $95.1 million recorded in Q2 2025.
  • Seres Therapeutics' Non-Current Assets' 5-year high stood at $183.2 million during Q4 2023, with a 5-year trough of $37.5 million in Q3 2021.
  • Moreover, its 5-year median value for Non-Current Assets was $98.1 million (2025), whereas its average is $105.9 million.
  • As far as peak fluctuations go, Seres Therapeutics' Non-Current Assets surged by 20063.83% in 2022, and later plummeted by 4485.0% in 2025.
  • Seres Therapeutics' Non-Current Assets (Quarter) stood at $51.2 million in 2021, then surged by 200.64% to $154.0 million in 2022, then grew by 18.94% to $183.2 million in 2023, then crashed by 44.79% to $101.1 million in 2024, then fell by 9.09% to $91.9 million in 2025.
  • Its Non-Current Assets stands at $91.9 million for Q3 2025, versus $95.1 million for Q2 2025 and $98.1 million for Q1 2025.